Salvage use of erlotinib in advanced non-small cell lung cancer with acquired resistance to gefitinib: Is a clinical benefit still achievable?

Chul Cho Byoung, Hang Kim Joo

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)678-680
Number of pages3
JournalAmerican Journal of Hematology/ Oncology
Issue number12
Publication statusPublished - 2007 Dec

All Science Journal Classification (ASJC) codes

  • Oncology

Cite this